Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Kura Oncology, with 10 buy, two hold and one sell rating among 13 analysts. The average 12-month price target is $25.62, well above the stock’s reported $11.89 opening price.
• Kura reported quarterly revenue of $20.87 million and an adjusted loss of $0.77 per share, beating analyst expectations of $20.16 million in revenue and a $0.88-per-share loss.
• Insider activity was mixed: CEO Troy Edward Wilson bought 100,000 shares, while insider Teresa Brophy Bair sold 31,487 shares. Company insiders collectively own 7.6% of Kura’s stock.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.6154.

Several research firms have recently commented on KURA. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Wedbush upped their price objective on Kura Oncology from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Thursday, August 13th. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th. Oppenheimer set a $24.00 target price on Kura Oncology in a report on Thursday, May 28th. Finally, Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, June 4th.

Kura Oncology Trading Up 1.5%

NASDAQ KURA opened at $11.89 on Friday. The stock has a market capitalization of $1.06 billion, a P/E ratio of -3.53 and a beta of 0.38. Kura Oncology has a 52-week low of $7.36 and a 52-week high of $12.90. The firm has a 50-day moving average price of $10.53 and a 200 day moving average price of $9.46. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Equities research analysts expect that Kura Oncology will post -3.23 EPS for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 31,487 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Troy Edward Wilson bought 100,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the completion of the acquisition, the chief executive officer owned 379,194 shares of the company's stock, valued at $4,216,637.28. This represents a 35.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 7.60% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of KURA. IFP Advisors Inc raised its holdings in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. Royal Bank of Canada grew its holdings in Kura Oncology by 7.6% in the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company's stock valued at $203,000 after purchasing an additional 1,375 shares during the last quarter. Allworth Financial LP grew its holdings in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company's stock valued at $43,000 after purchasing an additional 1,553 shares during the last quarter. Focus Partners Advisor Solutions LLC grew its holdings in Kura Oncology by 7.9% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company's stock valued at $238,000 after purchasing an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Kura Oncology by 10.0% in the fourth quarter. ProShare Advisors LLC now owns 18,572 shares of the company's stock valued at $193,000 after buying an additional 1,692 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source